NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., trading under the ticker NRXP, is a clinical-stage biopharmaceutical company focused on developing treatments for serious central nervous system and infectious disease conditions. The company's path to public markets involved a business combination with Big Rock Partners Acquisition Corp., a blank-check company sponsored by Big Rock Partners that targeted the healthcare and life sciences sector and completed its initial public offering in 2018. The firm filed a 10-Q quarterly report with the SEC in August 2018, reflecting its early public reporting activity. NRX Pharmaceuticals operates in the pharmaceutical and biotechnology industry. Investors and research professionals seeking full filing history, deal structure details, and real-time SPAC analytics for NRXP can sign up for complete data access on SpacDesk.